Dextromethorphan and guaifenesin use needs to be monitored very carefully in patients with "weak metabolizer" CYP2D6 enzyme stages and individuals who will be sedated. This mixture medication has a large median toxic dose (TD50) to median efficient dose (ED50) ratio (or therapeutic index) in these patients. To overview: Clinical investigations https://lorenzoqstsr.blog-mall.com/30703693/dextromethorphan-dxm-for-sale-in-germany-can-be-fun-for-anyone